Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...
Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...
The toxic bite of a Gila monster can kill a human, but a specific ingredient in the cocktail of the lizard's venom is the ...
Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications known as GLP-1 receptor agonists soared nearly 600% between 2020 and 2023 in people ...
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients. Weekly injections of the GLP-1 receptor agonist exenatide (Byetta, ...
Women prescribed a GLP-1 receptor agonist up to 2 years before conception were less likely to develop hypertensive disorders of pregnancy, gestational diabetes, have a preterm birth or cesarean ...
Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...
Coca-Cola brushes off threats of aluminum tariff, GLP-1 drugs and ‘potential regulatory changes’
At the same time, commodity prices continue to fluctuate as does demand – especially as more Americans are prescribed GLP-1 agonist drugs for weight loss and dramatically shift and reduce their ...
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...
A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback